1112, Guangzhou, China E-mail: [email protected]: 86 20 83827812 extn 51157 A rapid, sensitive and selective ultra-performance liquid chromatography mass spectrometry (UPLC-MS/MS) method was developed and validated for the quantification of atorvastatin and all its as-yet-identified metabolites in human plasma.
Atorvastatin, its metabolites, and the internal standard (IS) were isolated from human plasma by liquid–liquid extraction with ethyl acetate and then separated on an Acquity UPLC HSS T3 column (3.0 mm × 100 mm, 1.8 μm) using 0.05% (v/v) formic acid in water/acetonitrile (25 : 75, v/v) as the mobile phase.
Atorvastatin, also known as the brand name product Lipitor, is a lipid-lowering drug belonging to the statin class of medications.
By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease.
Potency is thought to correlate to tissue permeability as the more lipophilic statins such as atorvastatin are thought to enter endothelial cells by passive diffusion, as opposed to hydrophilic statins such as pravastatin and rosuvastatin which are taken up into hepatocytes through OATP1B1 (organic anion transporter protein 1B1)-mediated transport.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009.
This is mainly attributed to the high rates of dyslipidemia among diabetic patients which is believed to be one of the major factors accounting for the high percentage of deaths among diabetics due to cardiovascular disease (CVD) .
The differences in the lipid profile between diabetics (especially type 2 diabetics) and nondiabetics account for the increased CVD risk .